Mid-day round-up: OncoGenex, Amgen

Amgen said this morning that Nplate, its treatment for Idiopathic thrombocytopenic purpura, a rare bleeding disorder, has been approved by the FDA. Read a release here. The approval was expected, although last month Amgen said the FDA's decision had been delayed.